Parkinson’s disease (PD) is the second-most common neurodegenerative disorder that, according to DRG epidemiology, afflicts more than 1.5 million people in the EU5. Although PD treatment has been relatively stable in recent years, the treatment paradigm is complex. PD is heterogeneous, requiring individualized treatment, chronic polypharmacy, and frequent adjustments to achieve symptom control throughout a patient’s disease course. Moreover, two recent entrants (Xadago and Ongentys) have added more complexity to this largely generic market. With the treatment landscape poised to expand even further thanks to a dynamic pipeline of unique therapies designed to optimize levodopa, reduce the frequency and impact of motor response complications, or treat key nonmotor symptoms, understanding the many forces that drive EU neurologists’ clinical decision making in PD today is crucial for developers of new PD therapeutics entering an increasingly complicated market.

Questions Answered

  • How does the treatment paradigm evolve as PD progresses, especially regarding motor complications and nonmotor comorbidities? What are the typical patient pathways through treatment?
  • What factors influence drug selection and the treatment paradigm for primary motor symptoms, motor fluctuations, and dyskinesia as the disease progresses?
  • Which factors drive brand use in the highly generic PD market, and how do neurologists expect their use of branded therapies to change over the next year?

Product Description

Current Treatment: Provides physician insights on prescribing behavior, treatment paths, and the factors and perceptions driving brand use so that you can understand each brand’s performance and improve or defend your competitive position.

Table of contents

  • Detailed, Expanded Analysis (EU5)
    • Key Updates
      • November 2017
      • September 2017
    • Introduction to Current Treatment for Parkinson's Disease
      • Key Findings
      • Introduction to Current Treatment and Medical Practice for Parkinson's Disease
    • Physician Prescribing Practices
      • Key Findings
      • Patient Characteristics
        • Though Variable, PD Progress Is Marked by Worsening Severity, Polypharmacy, and Increasing Comorbidities
      • Physician Treatment Practices
        • Treatment Choice in PD Is Multifactorial and Variable
        • Time to Treatment Start
        • Treatment Rates
        • Brand and Product Use for Parkinson's Disease
        • Treatment Duration by Product
        • Use of Nonpharmacological Approaches
        • Prescribing Practices by Line of Therapy
        • Combination/Regimen/Comedication Analysis
      • Physician Insight on Compliance and Persistency
        • Compliance and Persistence Is High Among PD Patients
      • Sequencing of Treatment
        • Adjusting Levodopa Therapy and Prescribing Adjunctive Agents Are Common Treatment Strategies in PD Management
      • Recent and Anticipated Changes in Treatment Practices
        • Surveyed Neurologists Expect Brand Prescribing Will Increase Over the Next Year
    • Physician Insight on Medical Practice
      • Key Findings
      • Factors Influencing Treatment Practice
        • Factors Influencing Disease Management
        • Major Drivers of Brand Use/Treatment
        • Major Obstacles to Brand Use/Treatment
        • Insight on Treatment Failure/Brand Issues
    • Methodology
      • Primary Market Research Methodology
    • Appendix
      • Bibliography
      • Primary Market Research
        • Progression Between Lines of Therapy: Country-Level Data
        • Sequencing of Treatment: Country-Level Data
        • Major Drivers of Brand Use/Treatment: Country-Level Data
        • Major Obstacles to Brand Use/Treatment: Country-Level Data
        • Rationale for Treatment Switching and Discontinuation: Country-Level Data

Author(s): Bethany Christmann, PhD

Bethany Christmann, has been with DRG since 2015, and is a Senior Business Insights Analyst with the Central Nervous System/Ophthalmology team. In this role, she covers the neurology space, specializing in Parkinson’s disease and epilepsy; she provides expert insight and authors primary market research and forecasting content focused on these and other neurology indications. Prior to joining DRG, Bethany earned her in neuroscience from Brandeis University, where she studied the cellular interactions involved in memory consolidation and their link to sleep behavior.

Related Reports

Parkinson's Disease | Unmet Need | Detailed, Expanded Analysis: Psychosis in PD (US/FR/DEU/UK)

Parkinson’s disease (PD) is widely recognized as a motor disorder, but PD is also associated with a diverse set of nonmotor symptoms. Surveyed neurologists estimate that 20% of their PD pat...

View Details

Parkinson's Disease | Landscape & Forecast | Disease Landscape & Forecast

The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more...

View Details

Parkinson's Disease | Access & Reimbursement | Detailed, Expanded Analysis (US)

Since 2015, several new brands have launched in the United States for the treatment of motor and nonmotor symptoms in Parkinson’s disease (PD), and yet more are on the near-term horizon. Ch...

View Details

Parkinson's Disease | Epidemiology | Americas

DRG Epidemiology's coverage of Parkinson's disease (PD) comprises epidemiological estimates of key p...

View Details